Epoch Investment Partners Inc. Takes Position in DaVita Inc. (NYSE:DVA)

Epoch Investment Partners Inc. acquired a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 368,436 shares of the company's stock, valued at approximately $55,100,000. Epoch Investment Partners Inc. owned approximately 0.45% of DaVita at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of DVA. MML Investors Services LLC boosted its stake in DaVita by 1.3% in the third quarter. MML Investors Services LLC now owns 5,300 shares of the company's stock worth $869,000 after purchasing an additional 68 shares in the last quarter. Te Ahumairangi Investment Management Ltd grew its holdings in DaVita by 1.0% during the 3rd quarter. Te Ahumairangi Investment Management Ltd now owns 48,137 shares of the company's stock worth $7,846,000 after acquiring an additional 500 shares during the last quarter. Tidal Investments LLC increased its position in DaVita by 45.2% in the 3rd quarter. Tidal Investments LLC now owns 5,688 shares of the company's stock valued at $932,000 after acquiring an additional 1,771 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of DaVita by 134.6% in the third quarter. Franklin Resources Inc. now owns 54,901 shares of the company's stock worth $8,885,000 after acquiring an additional 31,502 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in DaVita by 17.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after buying an additional 92,014 shares in the last quarter. Institutional investors own 90.12% of the company's stock.

DaVita Stock Down 0.6 %

DVA traded down $0.84 during trading on Friday, reaching $138.72. The company had a trading volume of 278,010 shares, compared to its average volume of 837,814. The business's fifty day moving average price is $146.81 and its 200 day moving average price is $155.40. The company has a debt-to-equity ratio of 23.18, a current ratio of 1.26 and a quick ratio of 1.21. DaVita Inc. has a 12 month low of $130.96 and a 12 month high of $179.60. The company has a market cap of $11.10 billion, a P/E ratio of 12.91, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on DVA. Barclays upped their target price on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 price target on DaVita in a research report on Friday, February 21st. StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a report on Thursday, April 10th. Finally, Cowen reissued a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $166.33.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.